DIAGNOSTIC_TEST
No intervention
No intervention
Measuring Cardiovascular Performance and Blood Flow Using Common But Never Compared Methods.
Status
Completed
Phase
Not applicable
Enrollment
657
Locations
4
Results
Posted
Publications
0
Study summary
What the protocol is testing.
Measuring Cardiovascular Performance Using Common Methods in subjects.
Full detailed description
This study will conduct measurements of cardiovascular performance by echocardiography (Echo), Brain Natriuretic Peptide (BNP) blood serum levels and blood flow by volume plethysmography (VP) in subjects who meet the AHA/ACC criteria for screening for peripheral arterial disease (PAD).
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Sep 17, 2020
Study start
Aug 5, 2020
Primary completion
Dec 29, 2021
Study completion
Jan 14, 2022
Results posted
Jul 3, 2024
Registry updated
Jul 3, 2024
Outcomes
What the study measures.
Primary outcomes
Feasibility of Performing Echo, BNP, and VP on Human Subjects.
Time frame · Baseline
The feasibility of performing three common tests, Echocardiography (Echo), Brain Natriuretic Peptide (BNP) and volume plethysmography (VP), in the same subject was assessed. Each of the 657 participants were submitted to a brief non-invasive blood flow and cardiac performance test (plethysmography (VP) and Echocardiography (Echo)). Each of the 236 participants were subject to blood drawn test, Brain Natriuretic Peptide (BNP).
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 45 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * At least 50 Patients from New York Heart Association (NYHA) Class 1 (One or more AHA Risk Factors, asymptomatic), ≤75% (36) Male, ≥25% (12) Female * At least 50 Patients from NYHA Class 2 (symptomatic), ≤75% (36) Male, ≥25% (12) Female Exclusion Criteria: * Subjects on mechanical ventilation. * Subjects who require decisions by a medical power of attorney. * Subjects unable to safely perform forced expiration. * Subjects with known technically difficult (TDS) trans-thoracic echocardiographic windows.
Study locations
4 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Middle Georgia Heart and Vascular Center
Macon, Georgia, United States
Integrated Cardiology Group, LLC, d/b/a Bryan Heart
Lincoln, Nebraska, United States
JF Southwest Heart Clinic, P.A.
Houston, Texas, United States
Southwest Clinical Trials
Houston, Texas, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Nesiritide.
NCT IDStudyPhase / statusEnrollmentUpdated
PRIMARY-HF: Heart Failure Screening in Primary Care Using Point-of- Care
Universidade do Porto · Heart Failure
Not applicable
Recruiting
160
2026-07
Boston Medical Center Ultrasound Decongestion Study in Heart Failure
Boston Medical Center · Congestive Heart Failure · Volume Overload
Not applicable
Not yet recruiting
200
2026-06
Measurement Of NT-proBNP to Predict Outcomes in Surgery
Norfolk and Norwich University Hospitals NHS Foundation Trust · Vascular Surgical Procedure
Not applicable
Recruiting
200
2026-06
rhBNP for Prevention of Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI)
China National Center for Cardiovascular Diseases · AKI - Acute Kidney Injury · Cardiac Surgical Procedures
Phase 4
Not yet recruiting
694
2026-06
Utilising AI Analysis of Sounds To prEdict heaRt failurE decOmpensation
Cambridge University Hospitals NHS Foundation Trust · Heart Failure
Not applicable
Recruiting
250
2026-05
Venous Excess and Lung Ultrasound During Continuous Kidney Replacement Therapy in Critically Ill Patients
Chulalongkorn University · Acute Kidney Failure Stage 3
Not applicable
Completed
100
2026-05
Spironolactone Therapy in Chronic Stable Right HF Trial
Ottawa Heart Institute Research Corporation · Chronic Right-Sided Heart Failure · Pulmonary Arterial Hypertension
Phase 4
Completed
15
2026-05
Secondary Use of PARALLEL-HF Data
Novartis · Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)
Not applicable
Completed
236
2026-04
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.